| Market Cap | 43.31M | P/E | - | EPS this Y | 78.50% | Ern Qtrly Grth | - |
| Income | -294.43M | Forward P/E | -5.02 | EPS next Y | 65.50% | 50D Avg Chg | 54.00% |
| Sales | 1.05M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 20.00% |
| Dividend | N/A | Price/Book | 1.07 | EPS next 5Y | - | 52W High Chg | -65.00% |
| Recommedations | 2.00 | Quick Ratio | 4.54 | Shares Outstanding | 4.05M | 52W Low Chg | 421.00% |
| Insider Own | - | ROA | -41.82% | Shares Float | 1.92M | Beta | 2.57 |
| Inst Own | - | ROE | -281.41% | Shares Shorted/Prior | 139.69K/113.77K | Price | 0.55 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 6,548,622 | Target Price | 17.50 |
| Oper. Margin | -9,485.01% | Earnings Date | Mar 4 | Volume | 569,476 | Change | 0.15% |
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Souza Marcio | Director Director | Aug 25 | Buy | 0.5608 | 90,000 | 50,472 | 90,000 | 08/25/22 |
| Hanley Jr. Michael Conick | Chief Commercial Off.. Chief Commercial Officer | Jun 08 | Buy | 0.71 | 28,200 | 20,022 | 36,200 | 06/10/22 |
| Quinn Anthony G. | President & CEO President & CEO | Mar 16 | Buy | 2.344 | 80,079 | 187,705 | 550,540 | 03/18/22 |
| Quinn Anthony G. | President & CEO President & CEO | Mar 11 | Buy | 1.95 | 144,666 | 282,099 | 473,461 | 03/15/22 |
| Alspaugh Jonathan | Chief Financial Offi.. Chief Financial Officer | Mar 11 | Buy | 2.08 | 75,000 | 156,000 | 165,372 | 03/15/22 |
| Shanafelt Armen | Director Director | Dec 09 | Buy | 3.66 | 150,000 | 549,000 | 150,000 | 12/13/21 |
| Quinn Anthony G. | President & CEO President & CEO | Dec 09 | Buy | 3.73 | 53,634 | 200,055 | 328,795 | 12/13/21 |